| Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer J Tie, JD Cohen, K Lahouel, SN Lo, Y Wang, S Kosmider, R Wong, ... New England Journal of Medicine 386 (24), 2261-2272, 2022 | 424 | 2022 |
| SMAD2, SMAD3 and SMAD4 Mutations in Colorectal Cancer NI Fleming, RN Jorissen, D Mouradov, M Christie, A Sakthianandeswaren, ... Cancer research 73 (2), 725-735, 2013 | 377 | 2013 |
| Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2 FS Santiago, HC Lowe, FL Day, CN Chesterman, LM Khachigian The American journal of pathology 154 (3), 937-944, 1999 | 163 | 1999 |
| Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis M Christie, RN Jorissen, D Mouradov, A Sakthianandeswaren, S Li, F Day, ... Oncogene 32 (39), 4675-4682, 2013 | 156 | 2013 |
| PIK3CA and PTEN Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer FL Day, RN Jorissen, L Lipton, D Mouradov, A Sakthianandeswaren, ... Clinical cancer research 19 (12), 3285-3296, 2013 | 142 | 2013 |
| Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors FL Day, J Karnon, D Rischin Journal of clinical oncology 29 (24), 3270-3277, 2011 | 73 | 2011 |
| Angiotensin II (ATII)-inducible platelet-derived growth factor A-chain gene expression is p42/44 extracellular signal-regulated kinase-1/2 and Egr-1-dependent and mediated via … FL Day, LA Rafty, CN Chesterman, LM Khachigian Journal of Biological Chemistry 274 (34), 23726-23733, 1999 | 71 | 1999 |
| FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy FL Day, E Link, S Ngan, T Leong, K Moodie, C Lynch, M Michael, ... British Journal of Cancer 105 (4), 498-504, 2011 | 68 | 2011 |
| Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists FL Day, E Link, K Thursky, D Rischin Journal of Oncology Practice 7 (3), 141-147, 2011 | 68 | 2011 |
| A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer F Day, A Muranyi, S Singh, K Shanmugam, D Williams, D Byrne, K Pham, ... Targeted oncology 10, 99-109, 2015 | 60 | 2015 |
| Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation N Kothari, R Kim, RN Jorissen, J Desai, J Tie, HL Wong, I Farragher, ... Acta oncologica 54 (4), 487-492, 2015 | 59 | 2015 |
| Durable response of metastatic squamous cell carcinoma of the skin to ipilimumab immunotherapy F Day, M Kumar, L Fenton, C Gedye Journal of Immunotherapy 40 (1), 36-38, 2017 | 39 | 2017 |
| Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer FL Day, T Leong, S Ngan, R Thomas, M Jefford, JR Zalcberg, D Rischin, ... British journal of cancer 104 (2), 265-271, 2011 | 33 | 2011 |
| Oncologist provision of smoking cessation support: a national survey of Australian medical and radiation oncologists FL Day, E Sherwood, TY Chen, M Barbouttis, M Varlow, J Martin, ... Asia‐Pacific Journal of Clinical Oncology 14 (6), 431-438, 2018 | 20 | 2018 |
| ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA … E Segelov, P Waring, J Desai, K Wilson, V Gebski, S Thavaneswaran, ... BMC cancer 16, 1-8, 2016 | 18 | 2016 |
| Psychometric properties of leadership scales for health professionals: a systematic review MA Carlson, S Morris, F Day, A Dadich, A Ryan, EA Fradgley, C Paul Implementation Science 16, 1-22, 2021 | 16 | 2021 |
| Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal antibody FL Day, J Desai, CL Corless, MC Heinrich, J Zalcberg Medical Oncology 28, 162-164, 2011 | 15 | 2011 |
| Cetuximab alone or with irinotecan for resistant KRAS-, NRAS-, BRAF-and PIK3CA-wild-type metastatic colorectal cancer: the AGITG randomized phase II ICECREAM study JD Shapiro, S Thavaneswaran, CR Underhill, KP Robledo, CS Karapetis, ... Clinical colorectal cancer 17 (4), 313-319, 2018 | 13 | 2018 |
| Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC trial. J Tie, J Cohen, K Lahouel, SN Lo, Y Wang, R Wong, JD Shapiro, ... Journal of Clinical Oncology 40 (17_suppl), LBA100-LBA100, 2022 | 11 | 2022 |
| Gastrostomy dependency trends over 15 years of patients at a large tertiary referral center following the insertion of a prophylactic gastrostomy for chemoradiation for mucosal … A Fraser, C Odelli, B Britton, M Kumar, F Day, MT Tieu, C Wratten Asia‐Pacific Journal of Clinical Oncology 16 (5), e198-e206, 2020 | 7 | 2020 |
